The Illinois COVID-19 Pharmacy Vaccine Task Force

FAQs

IDPH FAQs Regarding The COVID-19 Vaccine
CDC recommends an observation period following vaccination with mRNA COVID-19 vaccines. Persons with a history of an immediate allergic reaction of any severity to a vaccine or injectable therapy and persons with a history of anaphylaxis due to any cause should be observed for 30 minutes. All other persons should be observed for 15 minutes.

For additional information, please go to:

https://www.cdc.gov/vaccines/covid-19/info-by-product/clinical-considerations.html?CDC_AA_refVal=https://www.cdc.gov/vaccines/covid-19/info-by-product/pfizer/clinical-considerations.html">
CDC considers a history of the following to be a contraindication to vaccination with both the Pfizer-BioNTech and Moderna COVID-19 vaccines:
  • Severe allergic reaction (e.g., anaphylaxis) after a previous dose of an mRNA COVID-19 vaccine or any of its components
  • Immediate allergic reaction of any severity to a previous dose of an mRNA COVID-19 vaccine or any of its components (including polyethylene glycol [PEG])*
  • Immediate allergic reaction of any severity to polysorbate (due to potential cross-reactive hypersensitivity with the vaccine ingredient PEG)*
* These persons should not receive mRNA COVID-19 vaccination at this time unless they have been evaluated by an allergist-immunologist and it is determined that the person can safely receive the vaccine (e.g., under observation, in a setting with advanced medical care available). Persons with an immediate allergic reaction to the first dose of an mRNA COVID-19 vaccine should not receive additional doses of either of the mRNA COVID-19 vaccines.

For additional information, please go to:

https://www.cdc.gov/vaccines/covid-19/info-by-product/clinical-considerations.html?CDC_AA_refVal=https://www.cdc.gov/vaccines/covid-19/info-by-product/pfizer/clinical-considerations.html

To review a CDC webinar regarding updates on allergic Reactions, contraindications, and precautions to COVID-19 vaccinations, please go to:

https://emergency.cdc.gov/coca/calls/2020/callinfo_123020.asp
The CDC defines an immediate allergic reaction to a vaccine or medication as any hypersensitivity-related signs or symptoms such as urticaria, angioedema, respiratory distress (e.g., wheezing, stridor), or anaphylaxis that occur within four hours following administration. Recommendations for patients with immediate allergic reactions to prior COVID-19 vaccinations or components of these vaccines are outlined in the next FAQ and in the referenced link below.

For additional information, please go to:

https://www.cdc.gov/vaccines/covid-19/info-by-product/clinical-considerations.html?CDC_AA_refVal=https://www.cdc.gov/vaccines/covid-19/info-by-product/pfizer/clinical-considerations.html
A new variant of the virus that causes COVID-19 has been identified in the United States, the United Kingdom, and 30 other countries. The new variant appears to be a more contagious form of COVID-19. Currently, this variant does not seem to make individuals sicker or lead to more deaths. Cases have now been reported in three US states (Colorado, California and Florida) and are not known to be linked to travel, which could indicate community spread. No cases caused by this new variant have been confirmed in Illinois yet. As more information is learned, IDPH will provide updates and notify the public if/when the variant is detected in Illinois. Illinois is increasing its surveillance for the variant by performing additional genomic testing on an increased number of specimens that have been collected.

For additional information, please go to the Illinois Department of Public Health website. https://www.dph.illinois.gov/covid19/faq/new-variant

References

Florida Department of Public Health. New COVID-19 variant found in Florida, marking the nations third confirmed case. New COVID-19 variant found in Florida, marking the nation’s 3rd confirmed case | WFLA Accessed December 31, 2020.
The FDA is aware of this issue, and it's working with Pfizer to determine the best path forward and will share additional updates when available. At this time, given the public health emergency, the FDA is advising that it is acceptable to use every full dose obtainable (the sixth, or possibly even a seventh) from each vial, pending resolution of the issue. However, since these are preservative free vials, it is critical to note that any further remaining liquid that does not constitute a full dose should not be pooled from multiple vials to create one.

References

Owermohle S. FDA says Pfizer vaccine vials hold extra doses, expanding supply. https://www.politico.com/news/2020/12/16/pfizer-vaccine-extra-doses-447117
No, do not reserve any COVID-19 vaccine doses for the second dose administration. For example, if you receive 100 doses, administer it to 100 patients. Second doses will be taken into account with future allocations.